MetaCap

AbbVie (ABBV) vs Merck (MRK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Merck (MRK) has outperformed AbbVie (ABBV) over the past year, gaining 36.8% versus a gain of 21.1%. Over five years, ABBV leads with a +145.6% price change compared with +68.9% for MRK. AbbVie is the larger company by market cap ($505.89 billion vs $329.65 billion), about 1.5 times the size.

On valuation, Merck trades at a lower forward P/E (14.9x vs 17.6x for AbbVie). Merck offers the higher dividend yield (2.51% vs 2.42%). Merck converts more of its revenue into profit, with a net margin of 28.1% versus 6.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABBV+21.13%MRK+36.78%
+64%+22%-20%
Nov 21, 20251 yearNov 20, 2026
ABBV+146.21%MRK+65.70%
+162%+72%-18%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABBV versus MRK key metrics
MetricABBVMRK
Share price$286.20$133.72
Market cap$505.89B$329.65B
1-day change+0.94%+0.69%
YTD return+25.26%+27.04%
1-year return+21.13%+36.78%
5-year return+145.64%+68.92%
P/E ratio (TTM)49.18135.07
Forward P/E17.6514.92
EPS (TTM)$5.82$0.99
Dividend yield2.42%2.51%
Annual dividend$6.92$3.36
Revenue (latest FY)$61.16B$65.01B
Revenue growth (YoY)+8.57%+1.31%
Net income (latest FY)$4.23B$18.25B
Gross margin70.24%74.80%
Operating margin24.65%—
Net margin6.91%28.08%
52-week high$302.93$156.92
52-week low$190.75$96.06
Distance from 52-week high-5.52%-14.78%
Analyst consensusbuybuy
Avg. price target upside+9.76%+20.80%
Average volume4.84M9.81M
Shares outstanding1.77B2.47B
Employees57,00073,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRK has outperformed ABBV by 15.7 percentage points over the past year.
  • Merck trades at a higher earnings multiple (135.1x vs 49.2x trailing P/E).
  • Merck is more profitable, keeping 28.1 cents of every revenue dollar as net income versus 6.9 cents for AbbVie.
  • AbbVie grew revenue faster in its latest fiscal year (+8.57% vs +1.31%).

About AbbVie

ABBV stock →

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 57,000 employees

About Merck

MRK stock →

Merck & Co., Inc. operates as a healthcare company worldwide.

Health Care · Biotechnology: Pharmaceutical Preparations · 73,000 employees

ABBV vs MRK FAQ

Which is bigger, AbbVie or Merck?

AbbVie (ABBV) is larger, with a market capitalization of $505.89B compared with $329.65B for Merck (MRK).

Which stock has performed better over the past year, ABBV or MRK?

MRK returned +36.78% over the past 12 months, compared with +21.13% for ABBV (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ABBV or MRK?

ABBV has the lower trailing P/E at 49.2, versus 135.1 for MRK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, AbbVie or Merck?

Merck has the higher yield at 2.51%, compared with 2.42% for AbbVie.

Are AbbVie and Merck in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons